Takeda Pharmaceutical 2021: Coming into view – PharmaLive
Our History | Takeda Pharmaceuticals
Japan's Takeda sells four diabetes products to Teijin Pharma for $1.25 bln | Nasdaq
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JIWT4VMMFZMYNIVD3VNO6F4G7A.jpg "Japan's Takeda sells four diabetes products to Teijin Pharma for $1.25 bln | Reuters")
Japan's Takeda sells four diabetes products to Teijin Pharma for $1.25 bln | Reuters
Vipidia and Vipdomet: two new products containing the DPP4 inhibitor alogliptin for type II diabetes
Missing safety risk emails draw $9bn Actos fine | Business | Chemistry World
Takeda Pharmaceutical Company - Wikipedia
Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos - The New York Times
Takeda Stock: A Pharmaceutical Gem From Japan (NYSE:TAK) | Seeking Alpha
Takeda loses cancer suit over Actos | The Japan Times
Takeda Pharmaceutical Company – Chemie-Schule
Takeda Pharmaceuticals | Products, Recalls & Controversies
Takeda sells 18 brands | PharmaBiz.NET
Takeda trial win in Hatch-Waxman case involving diabetes products upheld by Federal Circuit | Experience | Jones Day
Takeda Italia S.p.A. - Roma, Italien
Takeda liefert belastbare Ergebnisse für das Geschäftsjahr 2020 mit starken Margen und robustem Cashflow; Das zugrunde liegende Umsatzwachstum wird sich voraussichtlich im GJ2021 beschleunigen | Business Wire
Takeda Launches Three New Diabetes Treatments - MPR
Takeda Pharmaceutical 2021: Coming into view – PharmaLive
Takeda's $4B drug clears psoriasis in one-third of patients
35 Takeda Pharmaceuticals Actos Bilder und Fotos - Getty Images
2022 Annual Integrated Report
